Status:
UNKNOWN
Cell-free DNA Quantification for Predictive Marker of Palliative Chemotherapy
Lead Sponsor:
Pusan National University Yangsan Hospital
Conditions:
Cell-Free Nucleic Acids
Biomarkers
Eligibility:
All Genders
19+ years
Brief Summary
This study is design to address, as follows: 1. correlation between fluorescence-based CFD measurements and tumor burden (primary tumor size, number of metastatic sites) 2. fluorescence-based CFD mea...
Detailed Description
* It is important to check the response to chemotherapy. Currently, it is mostly evaluated as a radiologic response or, rarely the change of tumor markers. * In the case of radiologic response tests a...
Eligibility Criteria
Inclusion
- Patients with histologically or cytologically confirmed initially metastatic or recurrent cancer who are expected to undergo primary palliative chemotherapy (patients who relapse after adjuvant chemotherapy before/after existing surgery can also be enrolled regardless of period)
- Patients with definitive tumor burden (Patients who do not have residual lesions due to metastasectomy are excluded. However, measurable lesions according to RECIST 1.1 are not mandatory, and evaluable lesions are possible)
- ECOG PS 0-2
- Adequate bone marrow, renal function, liver function to receive chemotherapy
- Patients with informed consent form
Exclusion
- Patients with treating antibiotic treatment within 3 days of study enrollment due to overt or suspected infection
- Other serious illness or medical condition
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05227950
Start Date
January 1 2022
End Date
June 30 2024
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea, 50612